UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

Annals of oncology, 2022-12, Vol.33 (12), p.1269-1283

2022

Volltextzugriff (PDF)

Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study

Digestive diseases and sciences, 2022-11, Vol.67 (11), p.5107-5115

2022

Volltextzugriff (PDF)

SARS-CoV-2 and Plasmodium falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt

New microbes and new infections, 2020-11, Vol.38, p.100817, Article 100817

2020

Volltextzugriff (PDF)

Surface defects incorporated diamond machining of silicon

International Journal of Extreme Manufacturing, 2020-12, Vol.2 (4), p.45102

2020

Volltextzugriff (PDF)

Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials

ESMO open, 2023-02, Vol.8 (1), p.100771-100771, Article 100771

2023

Volltextzugriff (PDF)

Numerical Computation and Analysis of Cutting Forces during Nanometric Scratching of Silicon Carbide

Journal of the Institution of Engineers (India) Series C, 2022-02, Vol.103 (1), p.53-62

2022

Volltextzugriff (PDF)

Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations

Annals of oncology, 2018-10, Vol.29, p.viii258-viii258

2018

Volltextzugriff (PDF)

HALO 110-101: Phase Ib study of PEGPH20 in combination with cisplatin + gemcitabine (PEGCISGEM) or atezolizumab (ATEZO) + CIS + GEM (PEGCISGEMATEZO) in patients with locally advanced/metastatic cholangiocarcinoma and gallbladder cancer

Annals of oncology, 2018-11, Vol.29, p.ix66-ix66

2018

Volltextzugriff (PDF)

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202

ESMO open, 2024-06, Vol.9 (6), p.103488, Article 103488

2024

Volltextzugriff (PDF)

A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)

Annals of oncology, 2018-10, Vol.29, p.viii402-viii402

2018

Volltextzugriff (PDF)

Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial

Annals of oncology, 2019-07, Vol.30, p.iv127-iv127

2019

Volltextzugriff (PDF)

Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions

Annals of oncology, 2018-10, Vol.29, p.viii720-viii720

2018

Volltextzugriff (PDF)

[18 F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) response and survival analysis in a phase 1/2 trial of nab-paclitaxel (nab-P) + gemcitabine (gem) for metastatic pancreatic cancer (MPC)

European journal of cancer (1990), 2016-12, Vol.69, p.S118-S118

2016

Volltextzugriff (PDF)

RNA sequencing of intrahepatic cholangiocarcinoma reveals two prognostic subclasses

Journal of hepatology, 2017, Vol.66 (1), p.S460-S460

2017

Volltextzugriff (PDF)

P-100Phase IB study of sorafenib + evofosfamide in patients (pts) with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC): NCCTG N1153 (Alliance)

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii29-ii30

2016

Volltextzugriff (PDF)

4LBA A phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis

European journal of cancer (1990), 2014-11, Vol.50, p.196-196

2014

Volltextzugriff (PDF)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]

Oncolytic virotherapy, 2019-01, Vol.8, p.1-2

2019

Volltextzugriff (PDF)

Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma

Leukemia, 2005-01, Vol.19 (1), p.154-156

2005

Volltextzugriff (PDF)

84MO Tumour-only sequencing led to inflated tumour mutational burden estimation especially in under-represented ethnic groups

Annals of oncology, 2020-09, Vol.31, p.S274-S275

2020

Volltextzugriff (PDF)

Pancreatic cancer models exhibit interferon-independent resistance mechanisms to a Morreton hybrid oncolytic vesiculovirus

European journal of cancer (1990), 2022-10, Vol.174, p.S128-S128

2022

Volltextzugriff (PDF)

68P Post-treatment ctDNA analysis reveals patterns of HER2 therapy resistance in advanced HER2-amplified colorectal cancer

Annals of oncology, 2024-06, Vol.35, p.S33-S33

2024

Volltextzugriff (PDF)

130P Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations

Annals of oncology, 2023-10, Vol.34, p.S231-S232

2023

Volltextzugriff (PDF)

P-91 A retrospective analysis of maintenance strategies in metastatic gastric and gastroesophageal cancer

Annals of oncology, 2020-07, Vol.31, p.S119

2020

Volltextzugriff (PDF)

712TiP A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose

Annals of oncology, 2023-10, Vol.34, p.S492-S492

2023

Volltextzugriff (PDF)

1645P STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)

Annals of oncology, 2023-10, Vol.34, p.S908-S909

2023

Volltextzugriff (PDF)

1 – 25 von 299

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(275)
Mit Volltextzugriff
(253)

Publikationsform

Sprache

Englisch
(299)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study

SARS-CoV-2 and Plasmodium falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt

Surface defects incorporated diamond machining of silicon

Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials

Numerical Computation and Analysis of Cutting Forces during Nanometric Scratching of Silicon Carbide

Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations

HALO 110-101: Phase Ib study of PEGPH20 in combination with cisplatin + gemcitabine (PEGCISGEM) or atezolizumab (ATEZO) + CIS + GEM (PEGCISGEMATEZO) in patients with locally advanced/metastatic cholangiocarcinoma and gallbladder cancer

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202

A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)

Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial

Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions

[18 F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) response and survival analysis in a phase 1/2 trial of nab-paclitaxel (nab-P) + gemcitabine (gem) for metastatic pancreatic cancer (MPC)

RNA sequencing of intrahepatic cholangiocarcinoma reveals two prognostic subclasses

P-100Phase IB study of sorafenib + evofosfamide in patients (pts) with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC): NCCTG N1153 (Alliance)

4LBA A phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]

Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma

84MO Tumour-only sequencing led to inflated tumour mutational burden estimation especially in under-represented ethnic groups

Pancreatic cancer models exhibit interferon-independent resistance mechanisms to a Morreton hybrid oncolytic vesiculovirus

68P Post-treatment ctDNA analysis reveals patterns of HER2 therapy resistance in advanced HER2-amplified colorectal cancer

130P Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations

P-91 A retrospective analysis of maintenance strategies in metastatic gastric and gastroesophageal cancer

712TiP A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose

1645P STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)

Suchergebnisse filtern